Gemmus Pharma
company
About
Gemmus develops innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $3.30M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$5.10M
Gemmus Pharma has raised a total of
$5.10M
in funding over 2 rounds. Their latest funding was raised on
May 13, 2014 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 13, 2014 | Series B | $3.30M | 1 | — | — | Detail |
| Jun 28, 2012 | Series A | $1.80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Gemmus Pharma is funded by 1 investors.
Wilmington Investor Network
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Wilmington Investor Network
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
